Point72 Asset Management’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$987K Buy
25,300
+6,300
+33% +$204K ﹤0.01% 2843
2026
Q1
$618K Buy
19,000
+12,100
+175% +$389K ﹤0.01% 3030
2025
Q4
$243K Buy
+6,900
New +$244K ﹤0.01% 3564
2023
Q2
– Sell
-300,000
Closed -$5M – 2819
2023
Q1
$5M Buy
+300,000
New +$3.1M 0.02% 754

Other funds holding VKTX

Point72 Asset Management's VKTX Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 473,308 shares worth $18.5M. The stake represents 0.02% of the portfolio and ranks #935 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in VKTX as recently as Q4 2025.

Point72 Asset Management first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Point72 Asset Management held 473,308 shares of Viking Therapeutics worth $18.5M as of Q2 2026.
  • Viking Therapeutics was a new Point72 Asset Management position in Q2 2026.
  • Viking Therapeutics made up 0.02% of Point72 Asset Management's portfolio in Q2 2026, its #935 holding.
  • Point72 Asset Management first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.